EDENTREE ASSET MANAGEMENT Ltd Raises Position in Medtronic PLC $MDT

EDENTREE ASSET MANAGEMENT Ltd increased its stake in Medtronic PLC (NYSE:MDT) by 16.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 246,741 shares of the medical technology company’s stock after purchasing an additional 34,389 shares during the quarter. Medtronic accounts for 5.7% of EDENTREE ASSET MANAGEMENT Ltd’s portfolio, making the stock its 3rd largest position. EDENTREE ASSET MANAGEMENT Ltd’s holdings in Medtronic were worth $23,492,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. AXQ Capital LP grew its position in Medtronic by 25.6% during the second quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock valued at $862,000 after buying an additional 2,013 shares during the period. UMB Bank n.a. boosted its stake in shares of Medtronic by 65.8% during the 3rd quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock worth $13,170,000 after acquiring an additional 54,898 shares during the last quarter. Applied Finance Capital Management LLC bought a new stake in shares of Medtronic during the 3rd quarter valued at $1,308,000. Principal Financial Group Inc. grew its position in shares of Medtronic by 17.2% during the 3rd quarter. Principal Financial Group Inc. now owns 1,656,155 shares of the medical technology company’s stock valued at $157,732,000 after acquiring an additional 242,910 shares during the period. Finally, Willis Investment Counsel increased its stake in shares of Medtronic by 5.0% in the 3rd quarter. Willis Investment Counsel now owns 401,868 shares of the medical technology company’s stock worth $38,274,000 after purchasing an additional 19,192 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Stock Down 0.7%

Shares of MDT opened at $96.88 on Friday. The business’s 50 day moving average is $99.04 and its 200 day moving average is $96.70. The company has a market capitalization of $124.20 billion, a PE ratio of 26.99, a price-to-earnings-growth ratio of 2.43 and a beta of 0.71. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.02. The business had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a return on equity of 14.88% and a net margin of 13.00%.The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date was Friday, December 26th. Medtronic’s payout ratio is currently 79.11%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on MDT shares. Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a research report on Saturday. The Goldman Sachs Group set a $111.00 price objective on Medtronic and gave the stock a “neutral” rating in a research note on Wednesday, November 19th. Truist Financial cut their price objective on Medtronic from $107.00 to $103.00 and set a “hold” rating for the company in a research note on Wednesday. CICC Research initiated coverage on shares of Medtronic in a report on Friday, January 30th. They issued an “outperform” rating for the company. Finally, Citigroup began coverage on shares of Medtronic in a report on Tuesday, February 3rd. They set a “buy” rating and a $117.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, Medtronic currently has an average rating of “Moderate Buy” and an average price target of $110.84.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Regulatory/coverage win in Japan for Medtronic’s Symplicity Spyral renal denervation device and management commentary that the company is investing in rollout and hiring to support market development — supports revenue upside from a growing hypertension therapy. Medtronic’s blood pressure device wins coverage nod in Japan
• Positive Sentiment: Analyst upgrade: Mizuho moved Medtronic to a “strong-buy,” which can support buying interest and short-term momentum. Mizuho upgrade reported via Zacks
• Neutral Sentiment: Industry growth tailwinds — a separate report highlights expansion in non‑invasive therapies (HIFU) and robotics/image‑guided systems; positive for device sector demand but not a direct Medtronic headline. HIFU Market Competitive Landscape Report 2025
• Neutral Sentiment: Competitive update — Intuitive Surgical (ISRG) reports faster international procedure growth, which underscores competitive dynamics in robotics and could pressure Medtronic’s robotics expectations over time. ISRG’s International Growth Outpaces US
• Neutral Sentiment: Company commentary and Q3 earnings materials are out (transcript available) showing mixed results: solid robotics wins but offset by some legal and expense items — provides context for guidance and valuation debate. Medtronic (MDT) Q3 2026 Earnings Call Transcript
• Negative Sentiment: Multiple broker notes lowered expectations or targets (JPMorgan, Robert W. Baird; Leerink cut its target to $119) — analyst downgrades/target cuts weigh on sentiment and can amplify selling. JPMorgan low expectations
• Negative Sentiment: Planned layoffs: Medtronic will cut 81 roles at a California diabetes site as it readies the diabetes spin‑out; restructuring adds near‑term execution risk and uncertainty around the separations. Medtronic to cut 81 employees at California diabetes site
• Negative Sentiment: Broader skepticism in media pieces discussing mixed quarterly results, legal exposure and whether recent wins materially change Medtronic’s investment case — fuels analyst disagreement and investor caution. Mixed Q3 Results, Robotics Win and Legal Hit

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).